仑伐替尼、索拉非尼与安慰剂治疗放射性碘难治性分化型甲状腺癌的成本效果分析
研究采用马尔可夫模型,从有限社会视角比较仑伐替尼、索拉非尼与安慰剂治疗放射性碘难治性分化型甲状腺癌的成本效果,数据来源于SELECT和DECISION两项III期试验。结果显示仑伐替尼最具成本效果,ICER为每质量调整生命年25275美元(对比索拉非尼)和40869美元(对比安慰剂);索拉非尼对比安慰剂ICER为每质量调整生命年64067美元。
要点
- 仑伐替尼对比索拉非尼的ICER为每QALY 25275美元,对比安慰剂为40869美元。
- 索拉非尼对比安慰剂的ICER为每QALY 64067美元。
- 在支付意愿每QALY 100000美元下,仑伐替尼有80%概率为最优方案。
核心结论
- 本研究提示仑伐替尼是放射性碘难治性分化型甲状腺癌最具成本效果的治疗,尽管仑伐替尼和索拉非尼对比安慰剂均具有成本效果。
研究设计与样本
- 采用马尔可夫模型估算放射性碘难治性分化型甲状腺癌治疗的成本和健康获益。
- 概率和生存率取自SELECT试验(仑伐替尼对比安慰剂)和DECISION试验(索拉非尼对比安慰剂)。
- 采用双月周期长度和半周期校正,时间跨度為终生。
- 医疗成本和效用数据来自RedBook、Healthcare Cost and Utilization Project及已发表文献。
- 所有成本调整至2015年美元,按每年3%贴现。
主要发现
- 基础病例中,仑伐替尼对比索拉非尼的ICER为每质量调整生命年25275美元。
- 仑伐替尼对比安慰剂的ICER为每质量调整生命年40869美元。
- 索拉非尼对比安慰剂的ICER为每质量调整生命年64067美元。
- 治疗决策对治疗成本及仑伐替尼及其副作用相关的健康效用敏感。
- 可接受曲线显示在支付意愿每质量调整生命年100000美元下,仑伐替尼有80%时间为最优方案。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenvatinib (Lenvima®) and sorafenib (Nexavar®) are the two most recently Food and Drug Administration-approved drugs for treating radioiodine-refractory differentiated thyroid cancer (RR-DTC). Both demonstrated superior progression-free survival over placebo in their respective Phase III clinical trials. This study compared the cost-effectiveness of the two treatments with placebo from a limited societal perspective. METHODS: A Markov model was developed to estimate the costs and health benefits for treatment of RR-DTC. The probabilities and survival rates were obtained from two Phase III trials: the SELECT trial comparing lenvatinib to placebo, and the DECISION trial comparing sorafenib to placebo. A bimonthly cycle length and half-cycle correction were used for a lifetime time horizon. Medical costs and utility data were obtained from RedBook, Healthcare Cost and Utilization Project, and the published literature. All costs were adjusted to US$2015, discounted at 3% annually. Then second-order Monte Carlo simulation with distributions was conducted to obtain the acceptability curve to address the uncertainty around model inputs. RESULTS: In the base case, lenvatinib was the most cost-effective treatment compared to sorafenib (incremental cost-effectiveness ratio [ICER] = $25,275/quality-adjusted life year [QALY]) and placebo (ICER = $40,869). Sorafenib is also cost-effective compared to placebo (ICER = $64,067/QALY). The treatment decisions were found to be sensitive to the treatment costs and the health utility associated with lenvatinib and its side effects. The acceptability curve showed lenvatinib optimal 80% of time at WTP of $100,000/QALY. CONCLUSIONS: This study suggests that lenvatinib is the optimally cost-effective treatment for RR-DTC, although both lenvatinib and sorafenib are cost-effective compared to placebo.
引用
- Wilson L, Huang W, Chen L, et al. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Thyroid. 2017. PMID: 28486081. doi:10.1089/thy.2016.0572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。